王恺皞,蒋雄京

• 1:中国医学科学院阜外医院心内科

摘要(Abstract)：

<正>大动脉炎是指主动脉及其主要分支的慢性进行性非特异性炎症,亦可累及肺动脉以及更远的外周动脉,病因未明。1大动脉炎累及冠状动脉临床特点以及介入治疗大动脉炎主要引起管腔狭窄或闭塞,少数导致动脉扩张、假性动脉瘤或夹层动脉瘤,临床症状复杂多样。文献报道,大动脉炎冠状动脉受累的比例差异较大为10%~30%,大部分为冠状动脉开口及近段病变,受累患者中仅5%~20%有相应症状[1-2]。患者可出现严重心肌缺血,有典型心

关键词(KeyWords)： 大动脉炎;冠状动脉;介入治疗;新型支架

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王恺皞,蒋雄京

参考文献(References)：

• [1]Endo M,Tomizawa Y,Nishida H,et al.Angiographic findings and surgical treatments of coronary artery involvement in Takayasu arteritis.J Thorac Cardiovasc Surg,2003,125(3):570-577.
• [2]高国峰,张峻,高晓津,等.非感染性冠状动脉炎的研究进展.中国循环杂志,2015,30(10):1024-1026.
• [3]Rav-Acha M,Plot L,Peled N,et al.Coronary involvement in Takayasu's arteritis.Autoimmun Rev,2007,6(8):566-571.
• [4]杨丽睿,张慧敏,蒋雄京,等.566例大动脉炎患者的临床特点及预后.中国循环杂志,2015,30(9):849-853.
• [5]杨明,柏小寅,倪建佼,等.年龄≤30岁心肌梗死患者的临床特点分析.中国介入心脏病学杂志,2015,23(6):309-313.
• [6]Maksimowicz-Mckinnon K,Clark TM,Hoffmann GS.Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients.Arthritis Rheum,2007,56(3):1000-1009.
• [7]Peng M,Ji W,Jiang X,et al.Selective stent placement versus balloon angioplasty for renovascular hypertension caused by Takayasu arteritis:Two-year results.Int J Cardiol,2016,205:117-123.
• [8]Spaulding C,Teiger E,Commeau P,et al.Four-year follow-up of TYPHOON(trial to assess the use of the CYPHer sirolimuseluting coronary stent in acute myocardial infarction treated with Ball OON angioplasty).JACC Cardiovasc Interv,2011,4(1):14-23.
• [9]Dawkins KD,Grube E,Guagliumi G,et al.Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex,long coronary artery lesions from a multicenter,randomized trial:support for the use of drug-eluting stents in contemporary clinical practice.Circulation,2005,112(21):3306-3313.
• [10]Furukawa Y,Tarnura T,Toma M,et al.Sirolimus-eluting steut for instent restenosis of left main coronary artery in takayasu arteritis.Circ J,2005,69(6):752-755.
• [11]Moses JW,Leon MB,Pompa JJ,et al.Sirolimus-eluting stents versus standard stents in patient with stenosis in a native coronary artery.N Engl J Med,2003,349(14):1315-1323.
• [12]Grube E,Silbar S,Hauptmann KE,et al.TAXUS:six-and twelve-months results from randomized,double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions.Circulation,2003,107(1):852-855.
• [13]Kang WC,Han SH,Ahn TH,et al.Successful management of left main coronary artery stenosis with a paclitaxel-eluting stent in Takayasu's arteritis.Int J Cardiol,2006,108(1):120-123.
• [14]Cheng Z,Yue C,Shen Z,et al.Percutaneous coronary intervention in Takayasu's arteritis.Int J Cardiol,2011,151(2):231-232.
• [15]Sakai H,Oyama N,Kishimoto N,et al.Revascularization of malignant coronary instent restenosis resulting from Takayasu's arteritis using sirolimus-eluting stents.Int Heart J,2006,47(5):795-801.
• [16]Lee K,Kang WC,Ahn T,et al.Long-term outcome of drugeluting stent for coronary artery stenosis in Takayasu's arteritis.Int J Cardiol,2010,145(3):532-535.
• [17]Spacek M,Zimolova P,Veselka J.Takayasu arteritis:use of drug-eluting stent and balloon to treat recurring carotid restenosis.J Invasive Cardiol,2012,24(9):E190-E192.
• [18]Agarwal G,Vats HS,Raval AN,et al.Chronic total occlusion and successful drug-eluting stent placement in Takayasu arteritisinduced renal artery stenosis.Clin Med Res,2013,11(4):233-236.
• [19]Tanigawa J,Hoshiga M,Tsuji M,et al.Recurrent coronary instent restenosis in Takayasu's arteritis.Intern Med,2012,51(24):3443-3444.
• [20]Soeiro Ade M,Pinto AL,Henares BB,et al.Takayasu arteritis:stenosis after bare-meta l and drug-eluting stent implantation.Arq Bras Cardiol,2013,100(1):e8-e11.
• [21]Lee HK,Namgung J,Choi WH,et al.Stenting of the left main coronary artery in a patient with Takayasu's arteritis.Korean Circ J,2011,41(1):34-37.
• [22]Wang X,Dang A.Prognostic value of brachial-ankle pulse wave velocity in patients with Takayasu arteritis with drug-eluting stent implantation.Arthritis Care Res(Hoboken),2015,67(8):1150-1157.
• [23]Khouzam RN,Shaheen M,Aziz RK,et al.The important role of inflammatory biomarkers pre and post bare-mental and drugeluting stent implantation.Can J Cardiol,2012,28(6):700-705.
• [24]Niccoli G,Montone RA,Ferrante G,et al.The evolving role of inflammatory biomarkers in risk assessment after stent implantation.J Am Coll Cardiol,2010,56(22):1783-1793.
• [25]Saadoun D,Lambert M,Mirault T,et al.Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis:a multicenter experience.Circulation,2012,125(6):813-819.
• [26]Yambe M,Tomiyama H,Hiriyama Y,et al.Arterial stiffening as a possible risk factor for both atherosclerosis and diastolic heart failure.Hypertens Res,2004,27(9):625-631.
• [27]Katayama Y,Sato H,Kitajima S,et al.Aortitis syndrome with repeated restenoses of a drug eluting stent.Kyobu Geka,2009,62(5):364-368.
• [28]Yokota K,Shimpo M,Iwata T,et al.A case of Takayasu arteritis with repeated coronary artery restenosis after drug-eluting stent implantation successfully treated with a combination of steroids.Intern Med,2012,51(7):739-743.
• [29]Borg FA,Dasgupta B.Treatment and outcomes of large vessel arteritis.Best Pract Res Clin Rheumatol,2009,23(3):325-337.
• [30]Park MC,Lee SW,Park YB,et al.Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis.Rheumatology(Oxford),2006,45(5):600-605.
• [31]Camuglia AC,Randhawa VK,Lavi S.Takayasu arteritis involving the left main coronary artery treated with a bioresorbable vascular scaffold.Int J Cardiol,2015,190:1-3.